|
1）Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011; 331: 1439-43
|
|
|
|
2）Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011; 378: 676-83
|
|
|
|
|
3）Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011; 378: 667-75
|
|
|
|
|
|
4）Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011; 51: 454-61
|
|
|
|
|
|
5）Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010; 3: 522-7
|
|
|
|
|
|
6）Leinwand LA, Moss RL. Medicine. Chemically tuned myosin motors. Science. 2011; 331: 1392-3
|
|
|
|
|
|
7）Campia U, Nodari S, Gheorghiade M. Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events? Curr Heart Fail Rep. 2010; 7: 100-9
|
|
|
|
|
|
8）Teerlink JR, Metra M, Zaca V, et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev. 2009; 14: 243-53
|
|
|
|
|